Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy.

@article{Qian2016TargetingDC,
  title={Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy.},
  author={Yuan Qian and Honglin Jin and Sha Qiao and Yanfeng Dai and Chuan Huang and Lisen Lu and Qingming Luo and Zhihong Zhang},
  journal={Biomaterials},
  year={2016},
  volume={98},
  pages={
          171-83
        }
}
View on PubMed
doi.org
92 Citations
Highly Influential Citations
2
Background Citations
18
Methods Citations
3
Results Citations
2

Figures from this paper

92 Citations

Citation Type

Citation Type

Magnetic Enrichment of Dendritic Cell Vaccine in Lymph Node with Fluorescent-Magnetic Nanoparticles Enhanced Cancer Immunotherapy
TLDR
A biocompatible approach with which to improve the homing efficiency of DCs and subsequent anti-tumor efficacy, and track their migration by multi-modality imaging, with great potential applications for DC-based cancer immunotherapy is developed.
Synthetic Polymeric Mixed Micelles Targeting Lymph Nodes Trigger Enhanced Cellular and Humoral Immune Responses.
TLDR
The results showed that the small, sub-60 nm size of the self-assembled mixed micelles enables them to rapidly penetrate into lymphatic vessels and reach draining lymph nodes after subcutaneous injection and have demonstrated great potential for clinical applications as an effective antitumor vaccine for further immunotherapy.
Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses
TLDR
Overall, the suitability of CNPs as antigen vehicle to induce potent anti-tumor immune responses by activation and expansion of tumor antigen-specific CD8+ T cells is supported.
Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation.
Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB/PLGA nano-vaccine
TLDR
DDAB/PLGA NP was a potent platform to improve vaccine immunogenicity by p38 signaling pathway in BMDCs, enhancing transport of antigens to LNs, and higher immunity response.
Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Immunotherapy is revolutionizing cancer treatment. Vaccination of antigenic peptides has been identified as a promising strategy for cancer immunotherapy while insufficient immune responses were…
Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
TLDR
M2-like TAM dual-targeting nanoparticles (M2NPs), whose structure and function were controlled by α-peptide (a scavenger receptor B type 1 (SR-B1) targeting peptide) linked with M2pep (an M2 macrophage binding peptide), provide a potential strategy of molecular-targeted cancer immunotherapy for clinical application.
Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma.
Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 81 REFERENCES
Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
TLDR
The nanovaccine prolonged tumor-occurring time, inhibited tumor growth, and suppressed tumor metastasis in prophylactic, therapeutic, and metastatic melanoma models, respectively, and it was revealed that nanvaccine effectively enhanced IFN-γ secretion and CD8(+) T cell response.
Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response.
Receptor-mediated delivery of antigens to dendritic cells: anticancer applications.
TLDR
The various approaches and receptors that have been used for antigen targeting that may eventually be translated to alternative DC-based immunotherapies are discussed.
In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination
TLDR
By better harnessing the immunizing functions of maturing dendritic cells, antibody-mediated antigen targeting via the DEC-205 receptor increases the efficiency of vaccination for T cell immunity, including systemic and mucosal resistance in disease models.
Structure-based programming of lymph-node targeting in molecular vaccines
TLDR
Administration of structurally optimized CpG-DNA/peptide amph-vaccines in mice resulted in marked increases in LN accumulation and decreased systemic dissemination relative to their parent compounds, leading to 30-fold increases in T-cell priming and enhanced anti-tumour efficacy while greatly reducing systemic toxicity.
Enhancing Ef fi cacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
TLDR
This work highlights the tdLN as a target for cancer immunotherapy and shows how its antigen-experienced but immune-suppressed state can be reprogrammed with a targeted vaccine yielding antitumor immunity.
Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
TLDR
This work highlights the tdLN as a target for cancer immunotherapy and shows how its antigen-experienced but immune-suppressed state can be reprogrammed with a targeted vaccine yielding antitumor immunity.
Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance
TLDR
DEC-205 provides an efficient receptor-based mechanism for dendritic cells to process proteins for MHC class I presentation in vivo, leading to tolerance in the steady state and immunity after DC maturation.
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
TLDR
This work investigates whether nanoparticles can be used as a vaccine platform by targeting lymph node–residing dendritic cells via interstitial flow and activating these cells by in situ complement activation, and demonstrates generation of humoral and cellular immunity in mice in a size- and complement-dependent manner.
Targeting Antigens to Dendritic Cell Receptors for Vaccine Development
TLDR
The most attractive cell surface receptors, expressed on DCs used as targets for antigen delivery for cancer and other diseases, are discussed.
...
1
2
3
4
5
...